Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation plus immune checkpoint blockade in recurrent or refractory malignant lymphoma
NL-OMON50953Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2021
- Countries
- 1
01
Overview
Open-label trial in lymphosarcoma (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Interferon signature alteration, FDG PET-CT response and 1 more. Planned start Apr 2021; status: withdrawn.
02
Conditions
lymphosarcoma
Beyond the preview
Go deeper on NL-OMON50953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50953.